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Abstract. 
 
Most transformed cells have lost anchorage 
and serum dependence for growth and survival. Previ-
ously, we established that when serum is absent, ﬁ-
bronectin survival signals transduced by focal adhesion 
kinase (FAK), suppress p53-regulated apoptosis in pri-
mary ﬁbroblasts and endothelial cells (Ili  et al., 1998.
 
J. Cell Biol.
 
 143:547–560). The present goals are to iden-
tify survival sequences in FAK and signaling molecules 
downstream of FAK required for anchorage-dependent 
survival of primary ﬁbroblasts. We report that binding 
of the SH3 domain of p130Cas to proline-rich region 1 
of FAK is required to support survival of ﬁbroblasts on 
ﬁbronectin when serum is withdrawn. The FAK–
p130Cas complex activates c-Jun NH2-terminal kinase 
(JNK) via a Ras/Rac1/Pak1/MAPK kinase 4 (MKK4) 
pathway. Activated (phospho-) JNK colocalizes with 
c ´
 
FAK in focal adhesions of ﬁbroblasts cultured on ﬁ-
bronectin, which supports their survival, but not in ﬁ-
broblasts cultured on collagen, which does not. Cells of-
ten survive in the absence of extracellular matrix if 
serum factors are provided. In that case, we conﬁrm 
work of others that survival signals are transduced by 
FAK, phosphatidylinositol 3
 
9
 
-kinase (PI3-kinase), and 
Akt/protein kinase B (PKB). However, when serum is 
absent, PI3-kinase and Akt/PKB are not involved in the 
ﬁbronectin-FAK-JNK survival pathway documented 
herein. Thus, survival signals from extracellular matrix 
and serum are transduced by FAK via two distinct 
pathways.
Key words: ﬁbroblast • anchorage-dependent survival 
• focal contacts • MAP kinase • apoptosis
 
Introduction
 
Interactions of cells with the extracellular environment
regulate many basic cellular functions, including differen-
tiation, migration, cell growth, and programmed cell death
(apoptosis). Many such signals from the extracellular ma-
trix (ECM),
 
1
 
 including those required for cell survival, are
relayed to the intracellular signaling machinery by inte-
grins, heterodimeric transmembrane receptors with over-
lapping specificity toward ECM components (Damsky and
Werb, 1992; Hynes, 1992; Meredith et al., 1993; Howlett et
al., 1995; Giancotti and Ruoslahti, 1999). One way to study
the effects of ECM signals independently of signals from
other extracellular sources has been to deprive cells of sol-
uble factors from serum and then to analyze the effects of
specific ECM ligands on such functions as adhesion, mi-
gration, and survival and on activation of specific intracel-
lular signaling pathways. Using this approach, we con-
firmed that fibronectin (FN) is particularly effective in
providing survival signals for several cell types, and that
these survival signals are transduced by focal adhesion ki-
nase (FAK) (Frisch et al., 1996; Hungerford et al., 1996;
Ili  et al., 1998). We then demonstrated that the FN/FAK
survival signal suppresses an apoptosis pathway regulated
by the tumor suppressor p53 in fibroblasts and endothelial
cells (Ili  et al., 1998).
FAK is a novel type of nonreceptor protein tyrosine ki-
nase. Its central kinase domain is similar to that of other
nonreceptor protein tyrosine kinases (e.g., Src family ki-
c ´
c ´
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nases). The COOH-terminal region of FAK can also exist
as an independently transcribed protein (termed FAK-
related nonkinase [FRNK]). Both FAK and FRNK con-
tain a COOH-terminal focal adhesion targeting (FAT) do-
main. FAT mediates the association of FAK and FRNK
with sites of cell–substratum interactions (Hildebrand et
al., 1993; Richardson and Parsons, 1996). At these sites,
FAK and FRNK colocalize with integrins and other focal
adhesion components such as paxillin and vinculin. FRNK
also contains two proline-rich regions. Proline-rich region
1 (PR-1) (residues 712–718) is NH
 
2
 
-terminal to the FAT
domain and provides a binding site for the adaptor protein
p130Cas (Cas). PR-2 (residues 873–876) is within the FAT
site and interacts with Graf (GTPase regulator associated
with FAK), and to a lesser extent with Cas (Hanks and
Polte, 1997). The region of FAK NH
 
2
 
-terminal to its ki-
nase domain contains the autophosphorylation site (Y397),
which becomes phosphorylated in response to integrin
cross-linking, thus providing a binding site for the SH2 do-
main of Src-family kinases and for phosphatidylinositol 3
 
9
 
-
kinase (PI3-kinase) (Chen et al., 1996). The NH
 
2
 
-terminal
domain also contains a region with a significant homology
to band 4.1 (Girault et al., 1999) that may interact directly
or indirectly with the cytoplasmic domains of integrin 
 
b
 
subunits (Schaller et al., 1995). Disruption of the 
 
fn
 
 and
 
fak
 
 genes results in very similar embryonic lethal pheno-
types in mice, which suggests that FAK is a principal medi-
ator of signals induced by the binding of cells to FN
(George et al., 1993; Furuta et al., 1995). FAK has also
been implicated in signaling initiated by the binding of
receptors for various growth factors, neuropeptides, and
cytokines (Hanks and Polte, 1997; King et al., 1997;
Schlaepfer and Hunter, 1998). In fact, recent data indicate
that FAK can interact, at least indirectly, with receptors
for EGF and PDGF (Sieg et al., 2000). Thus, FAK likely
coordinates signals from multiple inputs.
FAK has been proposed to couple integrins and cyto-
skeletal proteins to multiple signaling pathways. Several
lines of evidence suggest that integrin activation of PI3-
kinase, c-Jun NH
 
2
 
-terminal kinase (JNK), and extracellu-
lar signal–regulated kinase (ERK) signaling pathways re-
quire FAK (King et al., 1997; Dolfi et al., 1998; Zhao et al.,
1998; Schlaepfer et al., 1999). However, data from other
groups suggest that integrins are able to activate at least
some of these pathways independently of FAK (Wary et
al., 1998; Giancotti and Ruoslahti, 1999; Oktay et al., 1999).
A high level of apoptosis results if FAK function is elim-
inated, by blocking its interaction with integrin 
 
b
 
1 cyto-
plasmic domain (Hungerford et al., 1996), by gene target-
ing, or by displacement of FAK from focal contacts after
introduction of the FAT domain, which acts as a domi-
nant-negative (DN) for the FAK survival function (Ili  et
al., 1998). Interestingly, we found that cells survive if they
overexpress FRNK, even though FRNK, like FAT, lacks a
kinase domain. Together, these data suggest that (a) as-
sembly of FAK-containing molecular complexes at focal
adhesion sites is required for survival of anchorage-depen-
dent, serum-deprived cells, and that (b) a region of FAK
(and FRNK) NH
 
2
 
-terminal to FAT contains a site impor-
tant for transduction of survival signals.
The goals of this study are twofold. The first is to iden-
tify the mechanism by which FAK conveys survival signals
c ´
 
from FN in primary fibroblasts after serum withdrawal.
We now report that both recruitment of Cas to the PR-1
region of FAK located in focal adhesion sites and phos-
phorylation of Cas are required to support survival. The
second goal is to determine the pathway downstream of
FAK that transmits the survival signals from FN. We now
report that FN survival signals conveyed by the FAK–Cas
complex require Ras. Downstream of Ras, signals that ac-
tivate ERK1/2 through the Raf1/MAPK kinase (MEK1)
cascade are not essential for survival of anchorage-depen-
dent primary fibroblasts on a FN matrix. In contrast, acti-
vation of a pathway involving Rac1, Pak1, MAPK kinase 4
(MKK4), and JNK1/2 is required. Furthermore, activated
(phospho–) JNK, but not activated ERK, is present in fo-
cal contacts in cells plated on FN, which supports survival,
but not in cells on collagen I, which does not. Thus, activa-
tion of JNK by MKK4 and its recruitment to focal contacts
appear to be critical for supporting anchorage-dependent
survival in primary fibroblasts in the absence of survi-
val signals in serum. Finally, we confirm that when se-
rum is present and cells are in suspension or are poorly
spread, FAK is also required. However, survival signals
are conveyed by a distinct pathway involving PI3-kinase
and Akt/protein kinase B (PKB) as reported previously
(Khwaja et al., 1997). PI3-kinase and Akt/PKB are not re-
quired for the FN-FAK-JNK survival pathway reported
here. 
 
Materials and Methods
 
Cells
 
Isolation of primary rabbit synovial fibroblasts (RSF) was described previ-
ously (Werb et al., 1989). Primary cultures were expanded up to passage 3
in DME containing 10% FCS supplemented with glutamine, nonessential
amino acids, and penicillin/streptomycin and frozen. Just before experi-
ments, cells were thawed and used between passages 4 and 8.
MKK4-null embryo stem (ES) cells and matched wild-type ES cells
(Yang et al., 1997) were grown and induced to form embryoid bodies as
described previously for FAK-null ES cells (Ili  et al., 1998).
 
Survival Assays in Nontransfected Cells
 
RSF were plated in DME supplemented with sodium pyruvate, nonessen-
tial amino acids, and penicillin/streptomycin, but without serum, on FN-
or collagen I–coated tissue culture plastic. Coating was done with 25 
 
m
 
g/
ml of FN (GIBCO BRL) or fibrillar collagen (Vitrogen) in PBS overnight
at 4
 
8
 
C, followed by washing with PBS. Survival was assayed 16 h later by
fixing the cells with 4% paraformaldehyde in PBS followed by adding 10
 
m
 
g/ml Hoechst 33342 (Molecular Probes) and counting condensed, bright
nuclei characteristic of apoptotic cells vs. large, lightly stained nuclei of
healthy cells (Ili  et al., 1998). When indicated, cultures contained 15 
 
m
 
M
LY294002 (IC
 
50
 
 5 
 
1.4 
 
m
 
M) or 50 nM wortmannin (IC
 
50
 
 5 
 
5 nM) to inhibit
PI3-kinase, or 20 
 
m
 
M PD98059 (IC
 
50
 
 5 
 
2 
 
m
 
M) (Calbiochem) to inhibit
MEK1/2. The LY294002 and wortmannin were added to the cells either
before adhesion, while the cells were in suspension, or 1 h after plating to
allow for cell attachment to the matrix substrate. The PD98059 was added
before adhesion. Survival was evaluated after 16 h. All survival assays
were performed at least three times, with triplicate samples recorded pho-
tographically every time. To confirm that the PD98059 was active, control
cultures and cultures pretreated with 20 
 
m
 
M PD98059 for 15 min in sus-
pension, were plated on FN for 30 min in serum-free medium. Cell lysates
were immunoblotted for total ERK or pERK levels using anti-ERK or
anti-pERK antibodies.
For analysis of apoptosis in wild-type and MKK4-null embryoid bodies,
wild-type and MKK4-null ES cells were grown in suspension for 12 d in
the presence of serum as described previously (Ili  et al., 1998) to permit
differentiation of a variety of cell types and elaboration of endogenous
c ´
c ´
c ´ 
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ECM. Serum was then withdrawn for 24 h, after which the embryoid bod-
ies were fixed in 4% paraformaldehyde and processed for assessment of
cell death by terminal deoxynucleotidyl transferase–mediated dUTP nick
end labeling (TUNEL) in situ staining according to the manufacturer’s in-
structions (Boehringer Mannheim).
 
Plasmids
 
Mutagenesis of FAK proline residues 712 and 713 to alanine to generate
FAK-P was performed according to the protocol outlined in the Mu-
taGene Phagemid kit (Bio-Rad) using oligonucleotide Ala 712/713 (5
 
9
 
-
GATGAAGCAGCAGCCAAGCCCAGC-3
 
9
 
), and a single-stranded
DNA produced from the ClaI-SmaI FAK fragment cloned into pBlue-
script. Mutations were always confirmed by DNA sequencing, and the
FAK fragment in pBluescript was cloned into the corresponding sites
within the mouse FAK cDNA in the pCDNA3 expression vector (Invitro-
gen). The FRNK construct was created as described (Ili  et al., 1998).
FRNK with mutated 712 and 713 residues (FRNK-P) was generated as de-
scribed above for FAK-P.
To construct the green fluorescent protein (GFP)-FRNK
 
D
 
FAT fusion
protein, the SnaBI-XhoI fragment from the GFP-FRNK expression vec-
tor was isolated and subcloned into a new pEGFP C1 plasmid (Clontech)
opened with SnaBI and XhoI. GFP-FRNK P
 
D
 
FAT was generated from
GFP-FRNK
 
 
 
P
 
 
 
in the same manner.
pSSR
 
a
 
 Cas SH3 expression vector was generated by self-ligation of
pSSR
 
a
 
 Cas plasmid (Nakamoto et al., 1997) after KpnI digestion.
DNA fragments were isolated from agarose gels using QIAquick Gel
Extraction Kit (Qiagen). All blunting and ligation reactions were per-
formed with either Blunting or Ligation kits (Takara; imported by Pan-
Vera Corporation). Plasmid DNAs were isolated using appropriate-size
Qiagen kits.
 
Other Reagents
 
The following investigators kindly provided cDNA constructs and other
reagents for this study: constitutively active and DN Pak1 constructs, Dr.
J. Chernoff (Fox Chase Cancer Center, Philadelphia, PA) and Dr. G.
Bokach (The Scripps Research Institute, La Jolla, CA); DN and constitu-
tively active RAS constructs, Dr. H. Bourne (University of California San
Francisco, San Francisco, CA); MKK4-null embryo stem cells and DN
MKK4 construct, Dr. R. Flavell (Yale University School of Medicine,
New Haven, CT) and Dr. R. Davis (University of Massachusetts Medical
School, Worcester, MA); full-length Cas mutant and Cas constructs, Dr.
H. Hirai (University of Tokyo, Tokyo, Japan) and Dr. T. Nakamoto (Uni-
versity of Tokyo); pJNK antibody control peptides, Dr. B. Jarvis
(Promega, Madison, WI); constitutively active and DN Rac1 constructs,
and DN RhoA and CDC42 constructs, Dr. M. Symons (Picower Institute
for Medical Research, Manhasset, NY).
 
Transfections and Apoptosis Assay
 
Primary RSF were plated on FN-coated wells (24-well dishes) at 
 
z
 
75%
confluence in DME supplemented with 10% FCS, glutamine, and nones-
sential amino acids and allowed to adhere and grow for 24 h on the FN-
coated wells. Immediately before transfection, adherent cells were washed
three times with serum-free DME supplemented with glutamine and non-
essential amino acids. Cells were then transfected using Lipofectamine
Plus in serum-free medium (GIBCO BRL) according to the manufac-
turer’s instructions. In brief, a total 0.5 
 
m
 
g of DNA per well in 24-well cul-
ture plates was used per transfection. In cotransfection experiments, we
used equimolar amounts of different plasmid DNAs adding up to a total
of 0.5 
 
m
 
g per well. In the Cas competition experiment, the 1:1 ratio of Cas-
SH3 to full-length Cas was equimolar, as described above, adding up to
0.5 
 
m
 
g of DNA. For 1:2, 1:3, and 1:4 ratios, Cas-SH3 was kept constant and
the amount of Cas multiplied by 2, 3, or 4 respectively, thus increasing to-
tal DNA transfected. Expression of the transfected constructs was
checked either visually by GFP expression or in cell lysates by Western
blotting. Cultures were analyzed at the indicated times between 8 and 48 h
after addition of the liposomes. For most experiments, analysis occurred
at 16 h. In each experiment, three randomly chosen fields were photo-
graphed per well, and at least three separate experiments were performed,
each using three wells. Photographs were taken using an inverted fluores-
cence microscope equipped with dual FITC/Hoechst filters (Nikon
Corp.). All cells expressing GFP were counted as either alive or apoptotic.
Cells not expressing GFP were not counted. The apoptotic index repre-
c ´
 
sents the percentage of GFP-positive cells that were scored as apoptotic
after Hoechst staining (Ili  et al., 1998).
 
Western Blots and Kinase Assays
 
To examine expression levels of transfected constructs, cells were lysed in
modified RIPA buffer (1% sodium deoxycholate, 0.1% SDS, 1% NP-40,
150 mM NaCl, 10 mM Tris/HCl, pH 7.4, 1 mM EDTA) containing freshly
added protease inhibitors (1 
 
m
 
g/ml aprotinin, 1 
 
m
 
g/ml leupeptin, 1 mM
PMSF). Lysates were precleared with protein G–Sepharose (Amercham
Pharmacia Biotech) and separated by SDS-PAGE using 4–20% gradients
of acrylamide. Gels were transferred to nitrocellulose and were blotted us-
ing antibodies that recognized specific domains of proteins, or hemaggluti-
nin or Myc tags. Monoclonal anti-hemagglutinin (HA.11) was purchased
from BAbCo and monoclonal anti-Myc (9E10) from Santa Cruz Biotech-
nology. Polyclonal anti-Cas antibody (N17; Santa Cruz Biotechnology)
against an epitope within the SH3 domain was used to detect expression
of the CasSH3 vs. full-length Cas. A polyclonal antibody against the
COOH-terminal region of FAK (JF1; Ili  et al., 1995) was used to detect
levels of transfected GFP-FAT, GFP-FRNK, and full-length FAK.
To detect matrix-dependent activation of MAP kinases (p38 mitogen-
activated, dual-action kinase [MAPK], ERK1/2, MKK4, and JNK1/2),
RSF were plated for 1 or 10 h on FN or collagen I in serum-free medium,
and lysed in RIPA buffer containing freshly added proteinase inhibitors as
described above, plus phosphatase inhibitors (1 mM Na
 
3
 
VO
 
4
 
, 1 mM NaF).
The positive control for evaluating p38 MAPK activation was obtained by
lysis of serum-starved RSF treated with 10 
 
m
 
g/ml anisomycin (Calbio-
chem) for 15 min. Equal amounts of proteins were run on SDS-PAGE,
transferred to nitrocellulose filters, and blotted with antibodies against the
indicated protein kinases or phosphorylated forms of these kinases. All
phospho-specific antibodies were obtained from New England Biolabs,
except anti-pJNK and its control peptide, which were purchased from
Promega Corporation. Antibodies against ERK1/2, MKK4, and JNK1/2
proteins were obtained from Santa Cruz Biotechnology, and HRP-conju-
gated secondary antibodies were obtained from Jackson ImmunoRe-
search. Signals were detected by enhanced chemiluminescence (Amer-
sham Pharmacia Biotech).
For assessing the kinase activity of JNK, RSF were cotransfected as de-
scribed above with Flag-tagged JNK1 or JNK2, GFP, or GFP and FAK.
16 h after transfection, RSF were washed with PBS and lysed in buffer
containing 1% NP-40, 1% sodium deoxycholate, 0.1% SDS, with 150 mM
NaCl, 1.5 mM MgCl
 
2
 
, 10% glycerol, 1 mM EGTA, 50 mM Hepes, pH 7.4,
containing freshly added protease and phosphatase inhibitor cocktails.
JNK1 and JNK2 were immunoprecipitated from the cleared lysates with
anti-Flag antibodies coupled to agarose beads (Kodak) for 4 h at 4
 
8
 
C. The
precipitates were washed two times with lysis buffer, and once with 50
mM Hepes buffer, pH 7.4, containing 150 mM NaCl, 0.5 mM NaF, and 0.5
mM Na
 
3
 
VO
 
4
 
. After washing, the immunoprecipitates were suspended in
40 
 
m
 
l JNK kinase buffer containing 10 
 
m
 
Ci/sample [
 
32
 
P]
 
g
 
ATP (3,000 Ci/
mmol; NEN/DuPont), 10 
 
m
 
M ATP, and 1 
 
m
 
g/sample of an NH
 
2
 
-terminal
glutathione 
 
S
 
-transferase–c-Jun fusion protein as substrate (Santa Cruz
Biotechnology), and incubated for 15 min at 30
 
8
 
C. The reaction was
stopped by addition of 2
 
3
 
 reducing SDS sample buffer, and the samples
were separated by 12.5% SDS-PAGE, transferred to a polyvinylidene dif-
luoride membrane, and analyzed by autoradiography. To determine the
levels of immunoprecipitated JNK, the membranes were probed with a
monoclonal anti-Flag antibody and detected by enhanced chemilumines-
cence. All kinase assays and Western blots were performed at least three
times.
 
Immunocytochemistry
 
Immunocytochemistry was carried out as described in Sieg et al. (1998). In
brief, cells were plated without serum on FN-coated coverslips and fixed
at indicated times with 4% paraformaldehyde/PBS. Cells were permeabi-
lized for 10 min in cold acetone. pJNK was detected using rabbit anti-
pJNK antibody, followed by a fluorescein-conjugated donkey anti–rabbit
secondary antibody. To ensure specific staining of pJNK by anti-pJNK, we
combined the anti-pJNK (10 
 
m
 
g/ml) with 100 
 
m
 
g/ml of the phosphopep-
tide used to generate the phospho-specific antibody, which should block
interactions of the antibody with pJNK in RSF. Homology scanning by
DNA Star software of the pJNK peptide sequence against the regions sur-
rounding the FAK autophosphorylation site (Y397) or kinase domain
(Y576/Y577) was carried out to assess the possibility that the anti-pJNK
antibody might cross react with FAK. Western blotting was also used to
verify that the anti-pJNK did not cross react with pFAK. In another con-
c ´
c ´ 
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trol, we used a nonphosphorylated version of the peptide, which should
permit staining of pJNK by anti-pJNK. F-actin was visualized by
rhodamine-phalloidin (Molecular Probes). GFP and GFP-FAT were vi-
sualized directly in samples. pJNK immune complexes were visualized
with rhodamine-conjugated secondary antibody. All immunocytochemical
staining was carried out at least three times.
 
Results
 
We used transfection approaches for determining the
domains of FAK that were important for transducing
survival signals in RSF plated on FN, and both pharmaco-
logical and transfection approaches for determining the
signaling intermediates downstream of FAK that transmit-
ted these survival signals. For transfection experiments,
RSF were initially plated on FN-coated substrates in the
presence of serum. Subsequently, RSF were washed to re-
move any traces of serum, transfected, and cultured for
the times indicated. The apoptotic index was determined
as described in Materials and Methods and in Ili  et al.
(1998). Furthermore, we compared the ability of nontrans-
fected RSF plated in serum-free medium on FN, which
supports survival, or on collagen I, which does not, to acti-
vate the signaling intermediates in the survival pathway
downstream of FAK that were implicated by the results of
the transfection experiments. Finally, we asked the extent
to which the survival pathway downstream of FN over-
lapped with the survival pathway downstream of survival
factors in serum.
 
FN Matrix Survival Signaling Requires the Cas-binding, 
PR-1 Region of FAK or FRNK and Focal
Contact Localization
 
Expression of a GFP-FAT fusion protein in RSF triggered
a high level of apoptosis within 16 h after transfection and
serum withdrawal (Fig. 1 A), confirming our previous data
(Ili  et al., 1998). GFP-FAT was detected initially in focal
contacts of spread cells 8–10 h after transfection. The ma-
jority of GFP-FAT–expressing cells subsequently rounded
up, and by 16 h they displayed condensed and fragmented
nuclei, characteristics of apoptotic cells. Cells expressing
GFP alone, or GFP and FAK, maintained the control level
of apoptosis (
 
z
 
25%) for at least 48 h. Surprisingly, expres-
sion of GFP-FRNK at a similar level did not promote
apoptosis, (Fig. 1, A and B; Ili  et al., 1998), although as
reported previously, spreading of replated cells was slower
than in cells expressing GFP-FAK (Gilmore and Romer,
1996; Richardson and Parsons, 1996; Ili  et al., 1998; Zhao
et al., 1998).
This striking difference in survival of FRNK and FAT
transfectants, despite the observation that both displace
endogenous FAK from focal contact sites (Fig. 1 C), sug-
gested that the region in FRNK NH
 
2
 
-terminal to FAT
contains a site(s) for interaction with molecule(s) critical
for transduction of survival signals from FN. To test
whether the PR-1 (712–718) sequence in that region is crit-
ical, we mutated prolines 712 and 713 into alanines (P712/
713A) in FRNK and FAK (GFP-FRNK
 
 
 
P
 
 
 
and FAK P, re-
spectively) (Fig. 1 D). Expression of these mutant proteins
resulted in high levels of apoptosis, similar to that caused
by expression of GFP-FAT (Fig. 1 E). Next, we expressed
a cDNA encoding only the region of FRNK NH
 
2
 
-terminal
c ´
c ´
c ´
c ´
 
to FAT (GFP-FRNK
 
D
 
FAT; Fig. 1 D). This also resulted
in a high level of apoptosis (Fig. 1 E), presumably because
this fragment, which is unable to displace endogenous
FAK from focal contacts, could act as a sink for important
components of the survival complex that would ordinarily
bind to PR-1 in endogenous FAK. In support of this idea,
cells expressing FRNK
 
D
 
FAT containing P712/713A
(GFP-FRNK P
 
D
 
FAT) survived at levels similar to those
of cells expressing GFP-FRNK or GFP alone (Fig. 1, D
and E).
 
Survival Signals from FN Mediated by FAK Require 
Cas with Functional SH3 and Substrate Domains
 
A strong candidate for a FAK- or FRNK-interacting mol-
ecule responsible for supporting survival signals from FN
in fibroblasts is Cas, as it has been clearly shown that the
SH3 domain of Cas binds preferentially and with high af-
finity to the PR-1 of FAK and FRNK (Polte and Hanks,
1995). We therefore expressed the Cas SH3 domain inde-
pendently, as a DN for wild-type Cas (Fig. 2 A, panel 1).
Coexpression of GFP-FRNK and the Cas SH3 domain
caused apoptosis at a level similar to that caused by ex-
pression of GFP-FAT (Fig. 2 A, panel 2). This could be
rescued by allowing wild-type Cas to compete with Cas
SH3 for interaction with GFP-FRNK in focal contacts.
Thus, coexpression of wild-type Cas and the Cas SH3 frag-
ment in a ratio of 4:1 did not cause apoptosis (Fig. 2 A,
panels 2 and 3). These data suggest that in RSF expressing
FRNK, Cas is required for transmission of matrix survival
signals from FN via interaction with the PR-1 of FAK/
FRNK.
Next, we tested the consequences for survival of delet-
ing each of the three principal functional domains of Cas.
We coexpressed GFP and FAK with mutant constructs of
Cas lacking the SH3 domain (Cas
 
D
 
SH3), the substrate do-
main (Cas
 
D
 
SD) in which Cas can be phosphorylated at
multiple sites, or the Src-binding domain (Cas
 
D
 
Src-BD)
(Fig. 2 B, panel 1). All were expressed at similar levels
(Fig. 2 B, panel 3). We observed a high level of apoptosis
after expression of Cas
 
D
 
SH3 (Fig. 2 B, panel 2), which
supports the results in Fig. 1 and Fig. 2 A and suggests that
interaction of FAK with Cas is essential for the transduc-
tion of survival signals from a FN matrix. We also found
that the substrate domain (SD) of Cas was required for
FAK-mediated survival, whereas the Src-binding domain
of Cas was not (Fig. 2 B, panel 2). All together, these data
suggest that Cas binding to PR-1 and Cas phosphorylation,
most likely by FAK itself, are important for transducing
survival signals in cells expressing GFP and FAK.
 
FAK-transduced Matrix Survival Signals Converge
on Ras
 
FAK is known to activate the Ras and MAP kinase path-
ways in fibroblast cell lines (Schlaepfer et al., 1994). Fur-
thermore, Cas has been implicated in communicating with
the Ras pathway via Crk (Dolfi et al., 1998). Therefore, we
introduced DN or constitutively active forms of Ras into
cells expressing GFP and FAK to determine whether sig-
naling via Ras is required to support survival of RSF on FN
in the absence of serum. Cotransfection of DN Ras with
GFP
 
1
 
FAK (Fig. 3), or transfection of DN Ras alone (not 
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shown), resulted in a high rate of apoptosis in RSF after se-
rum withdrawal. Coexpression of DN Ras with GFP
 
1
 
FAK
did not trigger elevated apoptosis if serum was present, in-
dicating that DN Ras was not acting as a broad-spectrum
signaling inhibitor. Confirming the importance of Ras for
this anchorage-dependent survival pathway, we deter-
mined that expression of constitutively activated Ras res-
cued RSF from apoptosis triggered by GFP-FAT (Fig. 3).
Figure 1. The PR-1 region of FAK/FRNK and focal contact lo-
calization are required for the transmission of FN matrix survival
signals. RSF plated on FN in the presence of serum were trans-
fected with wild-type FAK and GFP, GFP-FRNK, GFP-FAT, or
GFP-FRNK with mutations in PR-1. Cells were cultured subse-
quently in the absence of serum for the times indicated. The apop-
totic index was assessed by determining the percentage of trans-
fected cells (GFP-positive) showing condensed or fragmented
nuclei after staining with Hoechst dye. (A) Cells expressing
GFP1FAK for 16 h remain spread on a FN matrix (upper left panel). Cells expressing GFP-FAT for 16 h (upper right panel) are
rounded with condensed, fragmented nuclei. In cells expressing GFP-FAT for 8, 12, and 16 h (lower left panel), GFP-FAT initially lo-
calizes to focal contacts in spread cells. By 12 h, cells expressing GFP-FAT start to round. By 16 h, rounded cells have condensed nuclei
as detected by Hoechst staining (arrow). Adjacent cell not expressing GFP-FAT has a normal nucleus (indicated by asterisk). In cells
expressing GFP-FRNK for 16 h (lower right panel), GFP-FRNK localizes to focal contacts, but cells survive. (B) Expression levels of
FAK, GFP-FRNK, and GFP-FAT in RSF 8 h after transfection. All are expressed at similar levels as shown by Western blot using a
COOH-terminal FAK antibody. (C) GFP-FAT (upper row) and GFP-FRNK (lower row) both replace endogenous FAK in focal con-
tacts. GFP, but not endogenous FAK, which is detected by an antibody against the NH2-terminal domain of FAK (N-FAK), is present
in focal contacts of transfected cells (arrowheads). Nontransfected (GFP-negative) cells in the same field stain with N-FAK (arrows).
(D) Diagrammatic representation of constructs used to test the importance of PR-1 in FAK and FRNK for supporting survival of RSF
on a FN matrix (see text for description). (E) Apoptotic index for RSF transfected with constructs shown in D after 16 h. Mutation of
PR-1 in both FRNK and FAK promotes apoptosis at levels comparable to GFP-FAT. A GFP-FRNK mutant that does not localize to
focal contacts but has intact prolines 712–713 (GFP-FRNKDFAT) is pro-apoptotic, whereas the GFP-FRNK P mutant that does not lo-
calize to focal contacts (GFP-FRNK PDFAT) loses the ability to induce apoptosis. PBD, paxillin-binding domain. 
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FN/FAK-mediated Survival Is Linked to the
JNK Pathway
 
Ras relays a wide variety of signals from the cell surface to
the nucleus via a network of three distinct but closely re-
lated groups of MAPKs: ERK1/2, p38 MAPK, and JNK1/2
(Wary et al., 1998). We next examined whether any of
these pathways was involved in FN matrix survival sig-
naling.
The Ras–ERK pathway involves Raf1, which phosphor–
ylates MEK1/2, which in turn phosphorylate ERK1/2.
Coexpression of DN Raf1 or DN MEK1 with GFP and
FAK resulted in only a small increase in apoptosis com-
pared with control apoptosis levels in cells transfected
with GFP and FAK (Fig. 4 A), despite the observation
that cells expressing DN Raf1 or DN MEK1 showed re-
duced staining with pERK antibodies compared with cells
in the same field that did not express these constructs
(data not shown). Furthermore, survival of GFP-express-
ing RSF plated on FN in serum-free medium was not af-
fected when cells were treated with 10
 
3
 
 the IC
 
50
 
 concen-
tration of PD98059, a selective and potent inhibitor of
MEK1/2 (Fig. 4 A), although the activities of ERK1/2
were suppressed by this treatment, as assessed by immu-
noblotting lysates of control- or inhibitor-treated RSF, us-
ing an anti–pERK-specific antibody (Fig. 4 A). Using the
same antibodies, we compared levels of pERK1/2 in whole
lysates of nontransfected primary RSF plated either on
FN, a survival-promoting matrix, or on collagen I, which
does not support survival. At 1 h after plating, ERK1/2
were both activated similarly in cells on either substrate.
Although at 10 h after plating the activity of both ERKs
had decreased significantly, this occurred on both FN and
collagen I (Fig. 4 B). Thus, ERKs are activated equally in
response to matrices that do and do not support survival.
The data in Fig. 4 suggest that the Ras–ERK pathway is
not primarily responsible for transduction of matrix sur-
vival signals from FN in anchorage-dependent RSF.
Ras also transduces signals that communicate with
the JNK or p38 MAPK families. These signals can be
regulated further by the Rho family of small GTPases and
Figure 2. The Cas SH3 and
SD are required for transmis-
sion of survival signals from
FN and FAK. (A, panel 1)
Diagram of the domain struc-
ture of Cas and the isolated
Cas SH3 domain. (A, panel
2) Expression of isolated Cas
SH3 domain with GFP-
FRNK disrupts survival. Co-
expression of full-length Cas
and Cas SH3 in a 4:1 DNA
molar ratio restores survival.
(A, panel 3) Western blot of
lysates of cells transfected
with Cas SH3 or Cas, and
with both Cas and Cas SH3 at
increasing ratios of Cas
cDNA. A paxillin reblot of
the same membrane shows
that sample loading is similar
in all lanes. (B, panel 1) Dia-
grams of Cas cDNAs with de-
letions of the SH3 domain
(CasDSH3), the substrate-
binding domain (CasDSD),
or the Src-binding domain
(CasDSrc-BD). (B, panel 2)
Expression of CasDSH3 or
CasDSD triggers high levels
of apoptosis, whereas expres-
sion of CasDSrcBD does not.
(B, panel 3) Western blot
showing that all Cas con-
structs are expressed in RSF
at similar levels. Reblot of
the same membrane with an
anti-paxillin antibody shows
similar loading in all lanes. 
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by p21-activated serine/threonine kinases (Pak family)
(Clark et al., 1998; Dolfi et al., 1998; Hall, 1998; Sells et
al., 1999). To establish whether the Rho family of small
GTPases participates in FN survival signaling, we cotrans-
fected GFP and FAK with the DN mutants: N19RhoA,
N17Rac1, or N17cdc42. Only DN Rac1 effectively inter-
fered with survival (Fig. 5 A), whereas the DN forms of
RhoA and cdc42 did not (data not shown). Cotransfection
of GFP and FAK with DN Pak1 or DN MKK4 also re-
sulted in high rates of apoptosis, whereas constitutively
activated forms of Rac1 and Pak1, expressed at the same
levels as their DN counterparts, suppressed apoptosis
when coexpressed with GFP-FAT (Fig. 5 A). The DN
constructs did not trigger apoptosis when transfected into
cells cultured in the presence of serum (Fig. 5 A). Finally,
an antibody specific for an activated form of MKK4 (anti-
pMKK4) produced a strong signal in immunoblots of ly-
sates of nontransfected RSF plated in serum-free medium
on FN, but not in those from cells plated on collagen I
(Fig. 5 B).
If MKK4 is a critical intermediate in the FN-FAK sur-
vival pathway, we reasoned that MKK4-null cells, like
FAK-null cells (Ili  et al., 1998), should show abnormally
high apoptosis when cultured in the absence of serum. To
test this, we generated embryoid bodies by culturing wild-
c ´
 
type or MKK4-null ES cells in suspension culture for 12 d
in the presence of serum, allowing them to elaborate an
endogenous matrix. After serum withdrawal for 24 h, only
the MKK4-null embryoid body culture showed elevated
apoptosis (Fig. 5 C), confirming the importance of MKK4
for propagating matrix survival signals downstream of
FAK when serum is withdrawn.
Both JNK1/2 and p38 MAPK can be activated by
MKK4. Using antibodies specific for phosphorylated
forms of these kinases, we determined that JNK2 was
Figure 3. Ras is involved in the transduction of matrix-depen-
dent survival signals from FN and FAK. Expression of GFP-FAT
triggered high apoptosis in RSF cultured either in the presence or
absence of serum. DN Ras promoted a high level of apoptosis
when coexpressed with GFP1FAK in RSF in the absence, but
not in the presence of serum. Expression of constitutively active
(CA) Ras rescued GFP-FAT–mediated cell death of RSF plated
on FN in the absence of serum.
Figure 4. The ERK-MAPK pathway is not essential for support-
ing FN-FAK–dependent survival. (A) Cotransfection of DN
Raf1 or DN MEK1, along with GFP1FAK, resulted in only a
small increase in apoptosis compared with GFP1FAK alone.
Addition of the MEK1/2 inhibitor PD98059 at 103 the IC50 to
cultures of nontransfected RSF did not trigger elevated apopto-
sis. The PD98059 was active, as treated cultures (1) showed re-
duced levels of activated pERK1/2 compared with untreated cul-
tures (2). Levels of total ERK proteins were similar in both
cultures. (B) ERK1/2 were activated similarly by contact with
FN, which supports survival, or collagen I (CO), which does not.
Lysates of nontransfected RSF cultured in the absence of serum
for either 1 or 10 h, were immunoblotted using antibodies that
detect total ERK1/2, or phosphorylated pERK1/2.The Journal of Cell Biology, Volume 149, 2000 748
Figure 5. The JNK MAPK
pathway transduces survival
signals from FN-FAK via
Rac1/Pak1/MKK4 after se-
rum withdrawal. (A) Expres-
sion of DN Rac1, DN Pak1,
or DN MKK4, along with
GFP1FAK, triggered high
levels of apoptosis in RSF
cultured on FN in the ab-
sence, but not in the presence
of serum. Coexpression of
constitutively active forms of
Rac1 (CA Rac1) or Pak1
(CA Pak1) rescued cells from
GFP-FAT–mediated death.
The Western blot panels
show that CA and DN Rac1/
Pak1 construct pairs were ex-
pressed at similar levels in
RSF and that DN MKK4 was
expressed at a level similar to
the other constructs. (B) Ac-
tive MKK4 was detected in
lysates of cells plated on FN
but not on collagen I. Lysates
of RSF cultured in the ab-
sence of serum for either 1 or 10 h on FN or on collagen I were immunoblotted using antibodies that detect total MKK4 protein or
pMKK4. MKK4 protein levels were similar to one another on both matrices at each timepoint. Significant levels of pMMK4 were de-
tected only in lysates of RSF cultured on FN at the 1 h timepoint. (C) MKK4-null and wild-type (Wt) ES cells were grown in suspension
for 12 d in the presence of serum. Serum was withdrawn for 24 h and embryoid bodies were processed to detect DNA fragmentation by
TUNEL in situ staining. Only MKK4-null embryoid bodies showed increased TUNEL staining when serum was withdrawn. (D) JNK,
but not p38 MAPK, was activated in response to attachment to FN. Lysates of RSF cultured without serum for 1 or 10 h on FN or col-
lagen I (CO), were immunoblotted using antibodies that detect p38 MAPK protein or pp38, or JNK1/2 proteins or pJNK1/2. p38Almeida et al. Survival Signaling: Fibronectin via FAK to JNK 749
strongly activated and JNK1 weakly activated in nontrans-
fected cells plated on FN, but not on collagen I, for 10 h in
the absence of serum, whereas p38 MAPK was not acti-
vated significantly on either matrix (Fig. 5 D). This latter
result also suggests that MKK7, another potential MAP
kinase kinase that activates p38 MAPK, does not play a
role in this survival pathway. To visualize the FAK activa-
tion of JNK, we transfected GFP-FAK into RSF plated on
FN without serum and stained for pJNK after 16 h. Most
cells transfected with GFP-FAK showed extremely bright
pJNK staining relative to untransfected cells (Fig. 5 E). To
assess at the biochemical level whether FAK was capable
of activating JNK1/2, we cotransfected FAK or GFP along
with Flag-tagged JNK1 and JNK2 (Fig. 5 F). After 16 h, we
determined the activity of anti-Flag–precipitated JNK1
and JNK 2 using glutathione S-transferase–c-Jun as a sub-
strate. JNK1 and especially JNK2 were strongly activated
in cells transfected with FAK, whereas cells expressing
GFP alone showed very little activation of either JNK. To-
gether, these data suggest that JNK is activated by FAK
and that activation of the JNK pathway rather than the
ERK or p38 MAPK pathways, plays the major role in
transducing survival signals from FN and FAK in RSF
when serum survival factors are absent.
Activated JNK Is Localized in Focal Contacts and in 
the Nucleus in Response to FN but Not to Collagen I
Several upstream signaling molecules that our experi-
ments have implicated in the FN survival pathway, includ-
ing FAK and Cas, are localized in focal contacts. In con-
trast, the downstream target transcription factors of JNK
are nuclear. Therefore, we hypothesized that one or more
intermediate signaling molecules in the pathway, such as
JNK, might have a role to play in focal contacts as well as
in the nucleus. To test this possibility, we stained nontrans-
fected RSF, plated for 10 h in the absence of serum on
either FN or collagen I, with an antibody that detects du-
ally-phosphorylated T and Y within the catalytic core of
activated JNK1 and JNK2. Indeed, pJNK was detected
both in the nucleus and in focal contacts in cells plated on
FN (Fig. 6 A, upper left panel). In contrast, only faint, dif-
fuse staining for pJNK was detected in the cytoplasm and
nucleus of RSF plated on pro-apoptotic collagen I (Fig. 6
A, upper right panel). The specificity of the antibody for
pJNK was confirmed by absorption with a phospho-JNK
peptide: after absorption, no residual staining was de-
tected (Fig. 6 A, lower left panel), whereas a nonphosphor-
ylated version of the same peptide had no effect on stain-
ing (not shown). Antibody against whole JNK1/2 proteins
also stained focal contacts and the nucleus, although more
diffusely, amidst additional cytoplasmic staining (Fig. 6 A,
lower right panel). These localization data correlated well
with the biochemical data showing that pJNK levels were
lower in RSF plated on collagen I as compared with RSF
plated on FN (see Fig. 5 D). Interestingly, when matrix
survival signals from FN were interrupted by expression of
GFP-FAT, and the cells were observed before they started
to show signs of apoptosis (8–10 h), GFP-FAT, but not
pJNK, was detected in focal contacts (Fig. 6 B, upper row,
arrows). Nontransfected cells in the same field showed
strong focal contact staining for pJNK (Fig. 6 B, upper
row, arrowheads). In contrast, cells expressing GFP-
FRNK showed a similar intensity of staining for pJNK as
nontransfected cells in the same field (Fig. 6 B, middle
row). When levels of full-length FAK were increased by
transfection of GFP-FAK, staining for pJNK overall and
in focal contacts was much more intense than it was in un-
transfected cells, supporting the biochemical data and
showing that enhanced activation is associated with focal
contacts (Fig. 6 B, lower row).
When activation of pERK was examined using the same
approach, little or no pERK staining was detected in cells
expressing either GFP-FAT or GFP-FRNK. However, ex-
pression of GFP and FAK triggered intense staining for
pERK, but this was not located in focal contacts. Thus,
FAK can activate both ERK and JNK, but these activated
kinases are located in different regions of the cells. Taken
together, these data strongly suggest that recruitment and
activation of JNK at focal contact sites is part of the mech-
anism by which survival signals originating from FN are
transduced by FAK in anchorage-dependent fibroblasts
plated on FN.
FAK also Transduces Survival Signals from Serum, but 
by a Distinct Pathway
Work from several groups has reported that PI3-kinase
also binds to FAK (Chen et al., 1996) and promotes sur-
vival of epithelial and endothelial cells in the presence of
serum after loss of attachment from matrix (Frisch et al.,
1996; Marte and Downward, 1997), the converse condition
to that of the experiments described above, in which ma-
trix is provided and serum is withdrawn. To determine
the importance of PI3-kinase–mediated signaling for FN-
dependent vs. serum-dependent survival, we tested the
ability of the PI3-kinase inhibitors LY294002 and wort-
mannin to trigger apoptosis when added to cultures of
RSF in the presence and absence of serum, either at the
time of plating on FN or after the cells had adhered to FN
for 1 h. After 18 h, these inhibitors had not promoted ele-
vated apoptosis in RSF under any of these conditions (Fig.
7 A), indicating that the PI3-kinase pathway is not re-
quired for transducing survival signals downstream of FN.
However, if these inhibitors were added to RSF adhering
to collagen I, on which they cannot spread effectively
MAPK was only weakly activated on FN. Lysates of anisomycin-treated primary RSF were used as a positive control (CTL). The signal
for pJNK2 was particularly strong at 10 h in cells plated on FN. JNK1 and JNK2 protein levels in cells on FN and collagen were similar
to one another at each timepoint. (E) Active pJNK (rhodamine) is strongly visible in cells transfected with GFP-FAK (green), but re-
mains at low levels in adjacent untransfected cells (see nuclei with no corresponding GFP staining in the merged picture). Cells on FN in
the absence of serum were fixed and stained after 16 h. (F) FAK, but not GFP, activates JNK1/2 in RSF. Flag-tagged JNK1 or JNK2,
and FAK or GFP were coexpressed in RSF for 16 h after serum withdrawal. Cell lysates were incubated with anti-Flag antibody to pre-
cipitate JNK1/2. Precipitates were tested for their kinase activities using glutathione S-transferase–c-Jun as a substrate. JNK1/2 were ac-
tivated strongly by FAK, but not by GFP.The Journal of Cell Biology, Volume 149, 2000 750
Figure 6. (A) pJNK is de-
tected both in focal contacts
and in the nucleus in cells
plated on FN, but not in
cells plated on collagen I.
RSF plated on FN or col-
lagen I for 10 h were fixed,
permeabilized, and stained
with antibodies specific for
pJNK. Actin was detected
by rhodamine-phalloidin. In
cells on FN, strong staining
for pJNK was detected in the
nucleus and in focal contact
sites at the ends of actin
stress fibers (arrowheads). In
cells plated on collagen I,
stress fibers and focal con-
tacts were poorly developed.
Staining for pJNK was weak
and diffuse in the cytoplasm
and nucleus. As a control, the
anti-pJNK antibody was
added to RSF in the presence
of 100 mg/ml of the pJNK
peptide used to generate the
antibody. No focal contact
staining was detected (lower
left panel). Antibodies that
recognize all forms of JNK
1/2 showed a diffuse cytoplas-
within 1 h, or to RSF cultured in suspension, apoptosis lev-
els were very high even when serum was present (Fig. 7
B), confirming conclusions of others that when matrix sig-
nals are withdrawn, serum provides survival signals that
are conveyed by PI3-kinase (Khwaja et al., 1997; Marte
and Downward, 1997; Tamura et al., 1999). Our data that
expression of GFP-FAT kills RSF plated on FN regardless
of whether serum is present or not (Fig. 3), support the
conclusion that FAK transduces both the matrix and se-
rum survival signals. Coexpression of a constitutively acti-
vated form of Akt/PKB, a downstream target of PI3-
kinase, was unable to rescue apoptosis triggered by
GFP-FAT in RSF after serum withdrawal (Akt/PKB and
GFP-FAT, 89.3 6 13.9% apoptosis, vs. GFP-FAT alone,Almeida et al. Survival Signaling: Fibronectin via FAK to JNK 751
86.4 6 8.7%), supporting the conclusion that PI3-kinase is
not involved in transmitting FN-FAK survival signals. To
confirm that the activated Akt/PKB was functional in our
experiments, we showed that constitutively activated Akt/
PKB could decrease apoptosis triggered by overexpres-
sion of the FAK homologue, Pyk-2, in RSF when serum
was present (from 77.2 6 11.5% to 47.4 6 4.5%), in agree-
ment with the findings of Xiong and Parsons (1997).
These apparently conflicting findings regarding the im-
portance of PI3-kinase and Akt/PKB in transducing sur-
vival signals likely arise from the very different culture con-
ditions and cell types used. Our studies assessed survival of
primary fibroblasts attached to FN, a matrix that by itself
can support survival when survival signals from serum are
withdrawn. The other studies tested survival of other cell
types in the presence of serum, a condition that supports
survival when matrix survival signals are withdrawn. Thus,
anchorage-dependent and serum-dependent survival are
both regulated by FAK. However, the downstream path-
ways activated in the two conditions are distinct.
Discussion
Survival of anchorage-dependent cells is determined by
signals from their environment. These signals are prima-
rily derived from soluble factors present in serum and
from cell interactions with ECM. When serum factors are
withdrawn, cells can still survive on certain matrices,
whereas they undergo apoptosis on others. Previously, we
confirmed that FN is the most effective survival-promot-
ing ECM ligand for both primary fibroblasts and endothe-
lial cells after serum withdrawal, and showed that in con-
junction with FAK, it promotes a survival pathway that
suppresses p53-mediated apoptosis (Ili  et al., 1998). In
this study, we have focused on dissecting the matrix-
dependent survival mechanism downstream of FN and
FAK in primary fibroblasts. Our data suggest several con-
clusions (Fig. 8): (a) recruitment of Cas to the PR-1 region
of FAK located in focal contact sites, and its phosphoryla-
tion, are required for transmission of survival signals from
FN; (b) signals from the FAK–Cas complex activate a
Ras–JNK pathway; (c) activated JNK (pJNK) is localized
to focal contacts as well as to the nucleus in cells plated on
the pro-survival FN matrix; and (d) the FN-dependent sur-
vival pathway activated in RSF deprived of serum and the
serum-dependent survival pathway in these cells deprived
of matrix are both regulated by FAK, but are distinct from
one another.
Our initial observation of the striking difference be-
tween the ability of FAT vs. FRNK transfectants to sup-
port survival on a FN matrix in the absence of serum sug-
gested that the small NH2-terminal segment of FRNK
missing in FAT contained a survival sequence. We deter-
mined that this survival sequence is the PR-1 of FAK and
that it functions by binding the adaptor protein Cas via its
SH3 domain, thus potentially creating an adaptor platform
or scaffold with matrix-regulated kinase activity capable of
recruiting and activating multiple signaling molecules at
sites of contact with the ECM (see Fig. 8 and Schlaepfer et
al., 1999). The strict requirement that FAK (or FRNK) be
localized in focal contacts (Ili  et al., 1998; this study) (Fig.
1 C) in order for it to support survival points to its impor-
tance as a primary organizer and activator of these multi-
molecular signaling machines.
In its function as an adaptor protein, Cas can connect
signals initiated by FN and FAK to downstream pathways.
According to this model, Cas becomes phosphorylated on
tyrosines when bound to FAK, creating binding sites on
Cas for Crk and triggering the Cas-Crk-Ras connection
(Dolfi et al., 1998). Although FAK can both bind and
phosphorylate Cas, FRNK can only bind Cas. This raises
the question of how survival signals from FN might be
passed to the Ras pathway in cells that express FRNK
c ´
c ´
Figure 7. PI3-kinase is not required for transduction of survival
signals if cells are spread on a pro-survival matrix (i.e., FN)
whether or not serum is present, but is required to transduce se-
rum-dependent survival signals when a pro-survival matrix is
withdrawn. (A) PI3-kinase inhibitors Ly297082 and wortmannin
(Wort.) have no effect on the high survival of RSF plated on FN
whether or not serum is present. Inhibitors were added to cells at
the time of plating or to cultures 1 h after plating. Apoptotic in-
dex was measured 18 h later. (B) PI3-kinase inhibitors promote
apoptosis of cells plated on collagen I when serum is present.
These inhibitors do not alter the normally high apoptotic index of
cultures plated on collagen I in the absence of serum.
mic staining pattern as well as faint focal contact staining (arrowheads, lower right panel). (B) Expression of GFP-FAT (upper panels)
in RSF plated on FN in serum-free medium for 8–10 h (a time before appearance of apoptotic changes; see also Fig. 1), prevents pJNK
location in focal contacts (arrows). Staining for pJNK was strong in focal contact sites (arrowheads) of adjacent cells that were not trans-
fected. Expression of GFP-FRNK (middle panels) does not bar pJNK from focal contacts (arrows). pJNK staining in focal contacts of
GFP-FAT–expressing cells is similar in intensity to that in focal contacts of adjacent nontransfected cells (arrowheads). Expression of
GFP-FAK (lower panels) markedly increases pJNK staining in focal contacts (arrows) as well as in the cytoplasm, relative to adjacent
untransfected cells (arrowheads). (C) Staining for pERK in both GFP-FAT (upper panels) and GFP-FRNK–expressing RSF (middle
panels) is weak and not detected in focal contacts. pERK staining is strong in RSF expressing GFP-FAK (lower panels). However, focal
contact staining is not detected.The Journal of Cell Biology, Volume 149, 2000 752
rather than FAK in focal contacts and therefore form a
FRNK–Cas complex. Since Cas has a Src-binding domain,
one possibility is that the Src kinase substitutes for the
FAK kinase in phosphorylating Cas in cells expressing
FRNK, thereby generating binding sites for Crk. In sup-
port of this, we have found that RSF expressing FRNK re-
quire the Src-binding domain of Cas as well as the SH3
and SD (Ili , D., E. Almeida, and C. Damsky, manuscript
in preparation). As shown in Fig. 2 B, cells expressing
FAK do not require the Src-binding domain of Cas in or-
der to support survival. We have also found that expres-
sion of GFP-FRNK in fibroblasts derived from Src2/2
mouse embryos triggers apoptosis: the effects of FRNK
are indistinguishable from the effects of FAT in those
cells. In contrast, GFP-FRNK does not trigger apoptosis
when expressed in fibroblasts from wild-type embryos
(Ili , D., E. Almeida, and C. Damsky, manuscript in prep-
aration). Thus, it is likely that FRNK supports survival in
RSF because it can bind Cas, and because Src, which also
binds Cas, can supply the kinase activity required to phos-
phorylate Cas.
The FN-FAK-Cas survival pathway activates Ras. Con-
stitutively active Ras rescues death by FAT, whereas
c ´
c ´
blocking Ras function using a DN approach promotes
apoptosis of RSF when serum is absent, although not
when serum is present. This indicates both that DN Ras is
not acting as a general signaling inhibitor, and that the se-
rum survival pathway and FN survival pathway are dis-
tinct. Ras activation, in turn, can initiate multiple signaling
pathways, including the ERK, JNK, and p38 MAPK path-
ways. To determine whether these pathways were in-
volved in the transmission of matrix survival signals we
used several approaches. First, we determined which path-
ways were activated in cells that were on a pro-survival FN
matrix vs. a pro-apoptotic collagen I matrix. Then we in-
terrupted the pathways that we found were activated by
using both DN and inhibitor approaches. Finally, we
looked at the cellular localization of key signaling mole-
cules involved in survival.
Using these approaches, we determined that both the
ERK and JNK pathways were activated in adherent RSF.
However, ERK1/2 were activated similarly on FN and col-
lagen I, whereas JNK2 and to a lesser extent JNK1 were
selectively activated on a FN matrix. Additionally, inter-
rupting the ERK pathway either by expression of DN
forms of pathway intermediate or by pathway-inhibiting
Figure 8. Model of the FN-
dependent matrix survival path-
way activated in primary RSF
when serum is absent. FN sup-
ports the organization of a pro-
survival signaling complex based
on a FAK/Cas scaffold located at
focal adhesion sites. Paxillin
(Pax) is thought to participate in
the binding of FAK to focal ad-
hesion sites (Tachibana et al.,
1995). Cas is recruited to the sur-
vival complex via a FAK PR-
1–Cas SH3 interaction. Matrix
survival signaling also requires
an intact Cas SD. FN-FAK–asso-
ciated survival signals activate
Ras, and are propagated further
via a Rac1/Pak1/MKK4/JNK sig-
naling module, with pJNK de-
tected in focal contacts as well as
in the nucleus. This pathway is
distinct from the serum-depen-
dent survival pathway that is ac-
tivated when matrix is with-
drawn. The latter pathway
requires FAK, but it also re-
quires PI3-kinase, whereas the
FN-FAK pathway described
herein does not.Almeida et al. Survival Signaling: Fibronectin via FAK to JNK 753
drugs had a relatively small effect on FN-dependent sur-
vival, although they suppressed levels of pERK1/2. In con-
trast, interrupting the JNK pathway by expressing DN in-
termediates in RSF plated on FN triggered high levels of
apoptosis, whereas expressing constitutively active forms
of these intermediates at similar levels prevented death by
GFP-FAT. Expression of the DN forms in cells cultured
with serum did not trigger apoptosis, indicating that they
were not toxic or acting as general signal inhibitors.
The importance of JNK activation for the FN-FAK sur-
vival pathway was confirmed by demonstrating that em-
bryoid bodies derived from MKK4-null ES cells, like em-
bryoid bodies derived from FAK-null ES cells (Ili  et
al., 1998), displayed high levels of apoptosis when serum
was withdrawn, whereas embryoid bodies from wild-type
counterparts did not. Since MKK4 is the upstream activa-
tor of JNK1/2, these data suggest that the activation of
JNK is a central event in the transmission of survival sig-
nals downstream of FN and FAK when serum is absent.
Although FAK can activate the ERK pathway, this path-
way alone is likely neither sufficient nor necessary for sup-
porting matrix survival on FN. In contrast, considerable
evidence suggests that FAK activation of the ERK path-
way is important for regulating cell migration and cell-
cycle progression (Schlaepfer et al., 1999).
Interestingly, it appears that the difference in survival
signaling between FN and collagen I that is relevant to
their differential ability to support survival of RSF might
not be at the level of Ras activation (since ERKs are acti-
vated similarly by both matrices), but rather at the cou-
pling of Ras with the JNK pathway. Our data indicate that
under the culture conditions used, FN can couple Ras sig-
naling to JNK activation to a much greater extent than col-
lagen I. A key to this differential ability to activate the
JNK pathway may be the ability of FN, but not collagen I,
to recruit activated JNK as well as the other members of
the FAK-associated survival complex or scaffold to focal
contacts. In contrast, activated ERK is not detected in fo-
cal contacts in RSF plated on FN. Thus, pJNK may have a
distinct role to play when located in focal contacts that are
complementary to or independent of its transcriptional
role in the nucleus.
Activation of JNK has been previously associated with
apoptosis (Cardone et al., 1997; Frisch and Ruoslahti,
1997). Other recent studies have provided evidence both
in favor and against roles for JNK in caspase-mediated
(Chaudhary et al., 1999; Low et al., 1999) or etoposide-
mediated (Anderson et al., 1999; Jarvis et al., 1999) apop-
tosis. However, additional studies using the MKK4-null
mouse suggest that the absence of MKK4 does not inter-
fere with induction of apoptosis in response to etoposide,
cisplatinum, adriamycin, and gamma irradiation. Further-
more, apoptosis of hepatocytes and T cells was high in the
MKK4-null model, leading to death at embryonic day 12.5.
These data indicate that the MKK4/JNK pathway is criti-
cal for supporting survival of at least some cell types (Ga-
niatsas et al., 1998; Nishina et al., 1997, 1998, 1999; Yang et
al., 1997). Thus, there is precedence for a survival-promot-
ing role for the MKK4/JNK pathway. Interestingly, our
data show that JNK1 and 2 respond differently to plating
on FN and collagen (Fig. 5 D). JNK1 becomes transiently
phosphorylated in response to collagen as well as FN at
c ´
1 h, although the phosphorylation level is consistently
slightly greater in response to FN. In contrast, phosphory-
lation of JNK2 is delayed, long-lasting and a specific re-
sponse to FN in these cells. It is possible that this reflects
different roles of these two JNK isoforms in promoting
apoptosis vs. protecting cells from apoptosis. Although re-
solving specific roles for JNK 1 and 2 will require signifi-
cant additional work, it is clear that in our primary
fibroblast system, activation of the MKK4/JNK pathway is
required for FN matrix-dependent survival when serum
survival signals are absent.
Data from several groups document an important role
for PI3-kinase in supporting cell survival (Frisch and Ruo-
slahti, 1997; Marte and Downward, 1997; Tamura et al.,
1999). We therefore attempted to clarify conditions under
which PI3-kinase is and is not critical for survival in the
RSF system. Using an inhibitor approach, we confirm that
a FAK–PI3-kinase/AKT pathway in RSF is required for
survival when cells are cultured in the presence of serum
while in suspension (Tamura et al., 1999), or when plated
on an inappropriate matrix. However, our PI3-kinase in-
hibitor studies also showed that PI3-kinase is not required
for the FAK/Cas–MKK4/JNK matrix survival pathway,
which we show is activated when cells adhere to FN and
serum is absent.
We confirm that FAK is required for transduction of
signals from serum as well as from FN. This is most clearly
shown by the fact that interruption of FAK signaling by
expression of GFP-FAT promotes apoptosis in cells plated
on an appropriate matrix whether or not serum is present
(Fig. 3). Thus, the survival pathway activated in RSF ei-
ther by serum factors when matrix is absent (PI3-kinase)
or by FN when serum is absent (Ras/MKK4/JNK) shares
an upstream requirement for FAK, but then diverges. The
requirement for FAK in both situations is compatible with
its well-documented ability to be activated by both inte-
grins and serum components such as lysophosphatidic acid
and PDGF, and its capacity to associate with a large num-
ber of cytoskeletal and signaling molecules at focal contact
sites (Miyamoto et al., 1995, 1996; Sieg et al., 2000).
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